Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 142 results for "wallachbeth capital llc"

WallachBeth Capital Cuts uniQure NV (QURE) Price Target to $15.00
American Banking News

WallachBeth Capital Cuts uniQure NV (QURE) Price Target to $15.00

Filed Under: Analysts Price Targets • Market News uniQure NV (NASDAQ:QURE) had its price target decreased by WallachBeth Capital from $27.00 to $15.00 in a research report issued on Tuesday. The brokerage presently has a buy rating on the stock. American Banking News, 2 days ago
uniQure NV (QURE) Short Interest Update WKRB News, 2 months ago
American Banking News

Impax Laboratories Inc. (IPXL) Downgraded by WallachBeth Capital

WallachBeth Capital lowered shares of Impax Laboratories Inc. (NASDAQ:IPXL) from a buy rating to a hold rating in a research report report published on Monday. WallachBeth Capital currently has $18.00 target price on the specialty pharmaceutical ...
 WKRB News3 weeks ago Impax Labs (NASDAQ:IPXL) was Lowered by Analysts at WallachBeth to a Hold Rating Having $18.0 Target Price  Octafinance3 weeks ago DUPONT CAPITAL MANAGEMENT Corp Purchases New Stake in Impax Laboratories Inc (IPXL)  Zolmax News1 week ago Aravt Global LLC Has $64,341,000 Stake in Impax Laboratories Inc. (IPXL)  Zolmax News3 weeks ago
American Banking News

Esperion Therapeutics Inc. (ESPR) Price Target Raised to $0.00

Esperion Therapeutics Inc. (NASDAQ:ESPR) A number of other brokerages have also weighed in on ESPR. WallachBeth Capital lowered Esperion Therapeutics from a buy rating to a hold rating and set a $35.00 price objective on the stock. in a report on ...
 American Banking News1 month ago Credit Suisse Group AG Increases Esperion Therapeutics Inc. (ESPR) Price Target to $14.00  Mideast Time1 month ago Esperion Therapeutics Inc. (ESPR) Stock Rating Reaffirmed by Chardan Capital  American Banking News1 month ago Esperion Therapeutics Inc. (ESPR) Given Average Recommendation of Hold by Analysts  American Banking News1 month ago
Mideast Time

Ironwood Pharmaceuticals Inc. (IRWD) Position Held by Fisher Asset Management LLC

Fisher Asset Management LLC maintained its stake in Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 242,450 shares of the ...
 Mideast Time1 week ago State of Wisconsin Investment Board Has $9,528,000 Position in Ironwood Pharmaceuticals Inc. (IRWD)  Zolmax News3 weeks ago Vivus Inc. (VVUS) Posts Earnings Results, Beats Estimates By $0.10 EPS  Mideast Time4 weeks ago Airain ltd Buys New Stake in Ironwood Pharmaceuticals Inc. (IRWD)  WKRB News1 month ago

Leerink Swann Reiterates Outperform Rating for uniQure NV (QURE)

uniQure NV (NASDAQ:QURE) s stock had its outperform rating reiterated by equities researchers at Leerink Swann in a report issued on Friday. A number of other brokerages have also recently issued reports on QURE. Jefferies Group cut shares of ...
 SleekMoney1 day ago uniQure NV (QURE) Receives Outperform Rating from Leerink Swann  American Banking News1 day ago

Brokerages Set Akorn Inc. (AKRX) Target Price at $29.80

Shares of Akorn Inc. (NASDAQ:AKRX) have been given a consensus recommendation of Hold by the twenty research firms that are currently covering the stock. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold ...
 Mideast Time5 days ago Akorn Inc. (AKRX) Given Consensus Recommendation of Hold by Analysts  WKRB News6 days ago

Short Interest in Akorn Inc. (AKRX) Decreases By 15.3%

Akorn Inc. (NASDAQ:AKRX) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 10,324,737 shares, a decline of 15.3% from the October 31st total of 12,192,656 ...
 American Banking News1 week ago

Ironwood Pharmaceuticals (IRWD) Neutral Rating Reiterated at Wedbush

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) s stock had its neutral rating reiterated by research analysts at Wedbush in a report issued on Friday. They presently have a $13.00 price target on the stock. Wedbush's price objective would indicate a ...
 WKRB News2 weeks ago

NEXT WILD CARD FOR MARKETS : Italy's Constitutional Referendum

By Riva Gold and Giovanni Legorano After Brexit and Donald Trump, investors are focused on Italy as they position themselves ahead of what could be the latest political event to rattle markets and upend politics. If rejected, a Dec. 4 ...
 4 Traders3 weeks ago Next Wild Card for Markets: Italy's Constitutional Referendum -- Update  Morningstar.com2 weeks ago
Zolmax News

Zacks Investment Research Upgrades Akorn Inc. (AKRX) to Hold

Zacks Investment Research upgraded shares of Akorn Inc. (NASDAQ:AKRX) from a sell rating to a hold rating in a report published on Monday morning. According to Zacks, Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals ...
 WKRB News4 weeks ago Vivus Inc. (VVUS) Upgraded at Zacks Investment Research  Zolmax News4 weeks ago Zacks Investment Research Downgrades Vivus Inc. (VVUS) to Hold  Zolmax News4 weeks ago Vivus Inc. (VVUS) Downgraded to Hold at Zacks Investment Research  American Banking News1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less